# A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

> **NCT05279456** · PHASE3 · COMPLETED · sponsor: **Vaxine Pty Ltd** · enrollment: 39 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Advax-CpG55.2 adjuvanted recombinant spike protein

## Key facts

- **NCT ID:** NCT05279456
- **Lead sponsor:** Vaxine Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279456, "A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05279456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*